Navigation Links
SyntheMed Receives US Patent on Novel Polymer Technology
Date:7/30/2009

ISELIN, N.J., July 30 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion products, announced today that it has been awarded US Patent #7,569,643 pertaining to its bioresorbable reverse thermal gelation polymer technology. This represents the latest in a series of patents covering this novel technology and pertains to the application of these materials in the reduction of post-operative adhesion formation. Dr. Eli Pines, the Company's Vice President and Chief Scientific Officer stated, "The novelty of these materials is that they can be delivered to difficult to access sites in the body as a liquid through a syringe or as a spray and, once exposed to body temperature, rapidly transition to a resorbable, adherent, high viscosity gel. Thus, they are ideally suited as anti-adhesion materials in spine and tendon surgery."

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion products. The company is primarily focused on the commercialization of REPEL-CV(TM) Bioresorbable Adhesion Barrier and the advancement and expansion of product development programs based on its proprietary bioresorbable polymer technologies.

Statements in this Press Release that are not statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the company's efforts to obtain and maintain FDA and other required regulatory approvals; (ii) potential inability to secure funding as and when needed to support the company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the company's Annual Report on Form 10-KSB for the year ended December 31, 2008 for a description of these, as well as other, risks and uncertainties.


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SyntheMed Receives Frost & Sullivan Health Innovation Award Nomination
2. SyntheMed Receives Australian Regulatory Approval for REPEL-CV(R)
3. FDA Approves SyntheMeds REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery
4. SyntheMed Announces FDA Clearance of SinusShield(TM)
5. SyntheMed Announces New Management Appointments
6. SyntheMed Completes $4.0 Million Equity Placement
7. SyntheMed To Present at the AdvaMed 2008 MedTech Conference
8. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
9. SyntheMed Files Universal Shelf Registration
10. SyntheMed to Present at the Acumen BioFin Conference
11. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... 2017 , ... The Conference Forum and The Trout Group ... series of upcoming panels and events. The partnership culminates with the 4th Annual ... New York City. , “With our experience in producing the Immuno-Oncology 360° NYC event ...
(Date:8/14/2017)... ... August 14, 2017 , ... Opal Kelly, ... USB or PCI Express, announced the release of SYZYGY™, a new open standard ... the need for a compact, low cost, low pin-count, high-performance connectivity solution between ...
(Date:8/11/2017)... ... August 11, 2017 , ... Algenist continues to disrupt the skincare industry ... never before. , Collagen is the key structural element skin needs to maintain ... which include: , First to market with proprietary collagen ...
(Date:8/10/2017)... ... August 09, 2017 , ... The era ... clinic is here. The team at Capricor Therapeutics, Inc. utilized a cardiosphere-derived stem-like ... studies. , Dr. Travis Antes, head of analytical development at Capricor Therapeutics ...
Breaking Biology Technology:
(Date:6/30/2017)... Today, American Trucking Associations announced Seeing ... and eye tracking software, became the newest member ... "Artificial intelligence and advanced sensing algorithms ... driver,s attentiveness levels while on the road.  Drivers ... fatigue and prevent potential accidents, which could lead ...
(Date:5/16/2017)... -- Veratad Technologies, LLC ( www.veratad.com ), an innovative and ... solutions, announced today they will participate as a sponsor ... May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions of ... digital world, defining identity is critical to nearly every ...
(Date:4/19/2017)... , April 19, 2017 ... its vendor landscape is marked by the presence of ... is however held by five major players - 3M ... these companies accounted for nearly 61% of the global ... leading companies in the global military biometrics market boast ...
Breaking Biology News(10 mins):